Kite has announced that its CAR T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), a rare blood cancer with low survival rates, helped improve overall survival in 3-year follow-up data. Patients given the treatment had a median survival of 26 months, with 47% of patients alive at 36 months.
According to Emily Kimber, “The positive results come just days after the company closed a collaboration agreement with Arcellx to jointly develop and commercialise Arcellx’s late-stage CAR-T cell candidate to treat R/R multiple myeloma.”
To read more, click here.
(Source: PM Live, February 13th, 2023)